A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Journal Abstract

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.

Publication Date: 2024 Aug

Full Text Sources

Authors

E Hamilton; M Oliveira; N Turner; J García-Corbacho; C Hernando; E M Ciruelos; P Kabos; M Ruiz-Borrego; A Armstrong; M R Patel; C Vaklavas; C Twelves; V Boni; J Incorvati; T Brier; L Gibbons; T Klinowska; J P O Lindemann; C J Morrow; A Sykes; R D Baird

Abstract

OBJECTIVE

SERENA-1 (NCT03616587) is a phase I, multi-part, open-label study of camizestrant in pre- and post-menopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Parts A and B aim to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation.

Source

Annals of oncology : official journal of the European Society for Medical Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

38729567